Skip to main content
. 2013 Dec 20;124(1):251–261. doi: 10.1172/JCI67968

Figure 2. Soluble and aggregated AAT protein levels were reduced in PiZ mouse livers after AAT-ASO treatment.

Figure 2

(A) Six-week-old PiZ mice were treated for 8 weeks with PBS, 50 mg/kg/wk AAT-ASO, or control ASO via subcutaneous injection. hAAT mRNA levels in livers were quantified by qRT-PCR (TaqMan), and plasma AAT protein levels were determined by clinical chemistry analyzer. (B) IHC staining for AAT protein and PAS-D staining in liver. Scale bar: 50 μm. (C) Soluble and insoluble fractions from PiZ livers were analyzed by Western blot analysis with an anti-hAAT antibody. GAPDH was used as a loading control. BL, baseline. (D) Quantitation of soluble and (E) insoluble AAT protein from C. Results represent mean ± SD (n = 5–6 per group). **P < 0.01 by 1-way ANOVA with Tukey’s comparisons.